Essential Thrombin Residues for Inhibition by Protein C Inhibitor with the Cofactors Heparin and Thrombomodulin.
From: Departments of Pathology and Laboratory Medicine, and Pharmacology and Medicine, University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, NC, USA. yforten1@jhmi.edu
Journal of thrombosis and haemostasis : JTH
- Publish Date: Jul 2007
- ISSN: 1538-7933
- Volume: 5
- Issue: 7
- Pages: 1486-92
- Medium: Print
- Language: English
- Citation (JAMA): Fortenberry Y M, Whinna H C, Cooper S T, et al. Essential Thrombin Residues for Inhibition by Protein C Inhibitor with the Cofactors Heparin and Thrombomodulin.. J. Thromb. Haemost. Jul 2007;5:1486-92
Abstract
Background: Protein C inhibitor (PCI) and antithrombin (AT) are serine protease inhibitors (serpins) that inhibit a wide array of blood coagulation serine proteases including thrombin. OBJECTIVE: Fifty-five Ala-scanned recombinant thrombin mutants were used to determine thrombin residues important for inhibition by PCI with and without the cofactors heparin and thrombomodulin (TM) and compared with the prototypical serpin, AT. RESULTS: Residues around the active site (Tyr50 and Glu202) and the sodium-binding site (Glu229 and Arg233) were required for thrombin inhibition by PCI with and without cofactors. Exosite-2 residues (Arg89, Arg93, Glu94, Arg98, Arg245, Arg248, and Gln251) were critical for heparin-accelerated inhibition of thrombin by PCI. Exosite-1 residues (especially Lys65 and Tyr71) were required for enhanced PCI inhibition of thrombin-TM. Interestingly, we also found that the TM chondroitin sulfate moiety is not required for the approximately 150-fold enhanced rate of thrombin inhibition by PCI. Using the aforementioned thrombin exosite-2 mutants that were essential for heparin-catalyzed PCI-thrombin inhibition reactions we found no change in PCI inhibition rates for thrombin-TM. CONCLUSIONS: Collectively, these results show that (i) similar thrombin exosite-2 residues are critical for the heparin-catalyzed inhibition by PCI and AT, (ii) PCI and AT are different in their thrombin-TM inhibition properties, and (iii) PCI has a distinct advantage over AT in the regulation of the activity of thrombin-TM.
Mesh Headings (Keywords): Amino Acid Substitution, Binding Sites, Heparin, Humans, Models, Molecular, Multiprotein Complexes, Mutagenesis, Site-Directed, Protein C Inhibitor, Protein Conformation, Recombinant Proteins, Thrombin, Thrombomodulin
Check for Full Text / PubMed Unique Identifier (PMID): 17635698
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.